menu
    • menu
    [{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dalcetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dalcetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Qu\u00e9bec Government","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Series D Financing","leadProduct":"Dalcetrapib","moa":"CETP","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Qu\u00e9bec Government","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pharmaceuticals \/ Qu\u00e9bec Government"}]

    Find Clinical Drug Pipeline Developments & Deals for Dalcetrapib

    Menu

    Dalcetrapib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            DalCor Pharmaceuticals

                            Canada arrow
                            World Vaccine Conference
                            Not Confirmed

                            DalCor Pharmaceuticals

                            Canada arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalcetrapib

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Québec Government

                            Deal Size : $80.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            DalCor Pharmaceuticals Announces Dal-GenE-2 Confirmatory Trial and Closing of Series D Financing Round

                            Details : The financing will be used to conduct the Dal-GenE-2 confirmatory trial evaluating the potential of Dal-302 (dalcetrapib) to reduce the occurrence of fatal and non-fatal myocardial infarction in North America under a Special Protocol Assessment agreement...

                            Product Name : DAL-302

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 13, 2023

                            Lead Product(s) : Dalcetrapib

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Québec Government

                            Deal Size : $80.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            DalCor Pharmaceuticals

                            Canada arrow
                            World Vaccine Conference
                            Not Confirmed

                            DalCor Pharmaceuticals

                            Canada arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalcetrapib

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes Trial Results Published in European Heart Journal

                            Details : On fatal and non-fatal MI, the DAL-301 (dalcetrapib) treatment showed a relative risk reduction of 21% compared to placebo (5.9% vs. 7.3%; HR 0.79; 95% CI 0.65-0.96; p=0.02). Dalcetrapib was safe and well tolerated in the dal-GenE trial.

                            Product Name : DAL-301

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 21, 2022

                            Lead Product(s) : Dalcetrapib

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            DalCor Pharmaceuticals

                            Canada arrow
                            World Vaccine Conference
                            Not Confirmed

                            DalCor Pharmaceuticals

                            Canada arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalcetrapib

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DalCor Announces Dal-GenE Trial Continues with Final Data Expected in the First Half of 2021

                            Details : The independent dal-GenE Data and Safety Monitoring Board (DSMB) recommends the dal-GenE pivotal outcomes trial should continue as planned with no modifications. This is an important milestone for DalCor and for cardiovascular patients with the ADCY9 AA ...

                            Product Name : DAL-301

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 27, 2020

                            Lead Product(s) : Dalcetrapib

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth